Business
BioMark: 2025 Achievements & 2026 Vision
Celebrating A Year of Extraordinary AchievementVancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux.Dear BioMark Shareholders and Team,As we reflect on 2025, we celebrate a transformative year...
About this update from Biomark Diagnostics, Inc.
[{"type":"text","content":"Celebrating A Year of Extraordinary Achievement","length":47,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux.","length":387,"tagName":"p"},{"type":"text","content":"Dear BioMark Shareholders and Team,","length":35,"tagName":"p"},{"type":"text","content":"As we reflect on 2025, we celebrate a transformative year that positions BioMark as the leader in early cancer detection and precision diagnostics. What we've accomplished together represents not just scientific breakthroughs—it represents the resilience, dedication, and unwavering commitment of our team to a mission that saves lives.","length":340,"tagName":"p"},{"type":"text","content":"Key Achievements 2025","length":21,"tagName":"p"},{"type":"text","content":"Team & Capacity","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Expanded Technical Team: Strengthened scientific and operational capabilities with strategic talent additions","length":109,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":109,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Doubled Throughput Capacity: Scaled laboratory infrastructure to meet clinical and commercial demands","length":101,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":101,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"AI/ML Investment: Enhanced data analytics capabilities to improve diagnostic accuracy","length":85,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":85,"olType":false},{"type":"text","content":"Regulatory & Clinical Validation","length":36,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"ISO 15189 Certification Documents Submitted in Dec 2025: for international laboratory standards compliance, and once secured, it will help position us for CLIA and CAP accreditation as we enter the U.S. market","length"...